COVID19 continues to appear to be influenced marginally if at all by MS-DMT and probably vice versa. We are starting to see the case reports and I know some registry data is on the way
However the new epidemic is beginning to crank up . This is the publication epidemic and now it is over 500 new papers a day. It has become counter productive to try and keep up with it all. Most of them adding little. Scientists have been locked away for weeks and what else to do but write papers These are now surfacing as a sea of nothingness.
Multiple Sclerosis as a potential therapy against COVID-19? Emin GEMCIOGLU, Mehmet DAVUTOGLU, Ese Ece OZDEMIR, Abdulsamet ERDEN Publication stage: In Press Journal Pre-MSARDS
COVID-19 pandemic: the experience of a multiple sclerosis centre in ChileEthel Ciampi, Reinaldo Uribe-San-Martin, Claudia CárcamoDOI: https://doi.org/10.1016/j.msard.2020.102204Publication stage: In Press Journal Pre-ProofPublished online: May 16, 2020
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab Kulachanya Suwanwongse, Nehad ShabarekDOI: https://doi.org/10.1016/j.msard.2020.102201Publication stage: In Press Journal Pre-Proof
We also have the report that surfaced last week
COVID-19 in persons with multiple sclerosis treated with ocrelizumab – a pharmacovigilance case series Richard Hughes, Rosetta Pedotti, Harold KoendgenDOI: https://doi.org/10.1016/j.msard.2020.102192Publication stage: In Press Journal Pre-ProofPublished online: May 15, 2020.
They say “To date, over 160,000 MS patients worldwide have been treated with ocrelizumab (Roche, data on file, 2020). Here we present a summary of the available data, as of 30 April 2020, from ocrelizumab-treated pwMS with confirmed or suspected COVID-19 adverse event (AE) reports extracted from the Roche/Genentech global safety databases.Cases are defined as valid when at least an identifiable reporter, a single identifiable patient, a medicinal product and a suspected AE are provided (EMA, Guideline on GVP, 2017). AE reports can be flagged by the reporter as serious, based on their judgement, and are also designated serious by the company when regulatory definitions are met (EMA, ICH Harmonised Tripartite Guideline E2A, 1995). Patient characteristics such as age, gender, MS type, country of report, and details of ocrelizumab treatment are usually also provided.In the absence of an agreed COVID-19 severity classification, cases were assigned to categories based on the information provided: asymptomatic if it was explicitly stated that no symptoms were present, mild if non-hospitalised symptoms such as low-grade fever or cough were described, moderate if shortness of breath was reported, severe if pneumonia was present, and critical if requiring intensive care and/or mechanical ventilation. Outcome was classified as recovered, recovering (e.g. “doing well at home”, or “improving”), or not reported. Where no information was provided on a given parameter, this was captured as “not reported”.As of 30 April 2020, Roche/Genentech have received 100 validated AE reports of confirmed or suspected COVID-19 in ocrelizumab-treated pwMS as part of standard post-marketing pharmacovigilance.
In cases where COVID-19 symptom severity was provided (n=77), 49 were asymptomatic/mild/ moderate (64%), 23 (30%) severe and five critical (6%). All cases where outcome of COVID-19 was provided were reported as either recovered or recovering (64/64, 100%).
So this is good news that all people it seems were getting better, that thirty percent was severe is consistent with influences of the general population but may be a little higher. 26% of people were hospitalised and this is a little higher than reported from China were about 20% were hospitalised. and begs the question why.